The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
- 
      
  
Rapid Response Innovation Awards, 2011The Development of Novel Adeno-associated Virus Vectors for Intravenous Parkinson's Gene TherapyObjective/Rationale: 
 As Parkinson disease progresses, a wide range of brain areas exhibit evidence of inflammation and degeneration, but presently no therapies exist that selectively target these...
- 
      
  
Rapid Response Innovation Awards, 2011Developing and Characterizing Anti-Alpha-Synuclein Nanobodies from an Immune Phage Display LibraryObjective/Rationale: 
 This project uses a novel approach to deal with alpha-synuclein, which accumulates abnormally in Parkinson’s disease (PD). Cutting-edge recombinant antibody technologies will...
- 
      
  
Rapid Response Innovation Awards, 2011Ability of a Mitochondria Improver, Berberine, to Attenuate Parkinson's DiseaseObjective/Rationale: 
 Mitochondrial dysfunction is a central modification underlying the damage of dopamine neurons in Parkinson’s disease (PD). Our hypothesis is that drugs able to stabilise...
- 
      
  
Rapid Response Innovation Awards, 2011Alpha-synuclein May Be Responsible for the Link Between Parkinson's Disease and MelanomaObjective/Rationale: 
 Although the association between Parkinson’s disease (PD) and melanoma has been well established, biological explanations are still lacking. PD-causing gene alpha-synuclein is...
- 
      
  
MJFF Research Grant, 2010Male transgenic rat Parkinson's disease model characterizationPromising Outcomes of Original Grant: 
 The original project focused on the creation and characterization of pre-clinical models that express mutations in the protein alpha-synuclein that are known to...
- 
      
  
MJFF Research Grant, 2011Identification of Nrf2 Activators Using an In Silico Modeling Platform, Followed by Evaluation of These Compounds in an Alpha-Synuclein Model of PDObjective/Rationale: 
 Oxidative stress has been implicated in the etiology of Parkinson’s disease (PD). Under such conditions, the transcription factor NF-E2-related factor (Nrf2) binds to antioxidant...
 
  Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.